KALY Announces New Website For Its RespRx CBD Formulation To Treat COPD Affecting 65 Million Worldwide
August 23 2019 - 9:56AM
InvestorsHub NewsWire
KALY Announces New Website For Its
RespRx CBD Formulation To Treat COPD Affecting 65 Million
Worldwide
Dallas, TX -- August 23, 2019 --
InvestorsHub NewsWire -- Kali-Extracts, Inc. (Kali, Inc.
dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today published a new website dedicated to
providing information on the company’s recently introduced CBD
Formulation, RespRx, for the treatment of Chronic Obstructive
Pulmonary Disease (COPD) affecting 65 million people
worldwide. KALY introduced the new CBD Formulation earlier this week after making
a patent application and trademark registration for the
formulation. The website will be continually updated with
information about the patent and application trademark progress and
the ongoing RespRx medical trials and developments as the company
advances toward FDA approval.
www.RespRx.com
US Patented Cannabis
Extraction Process For Development Of Cannabis
Therapies
In the fourth quarter of last year,
2018, KALY acquired NCM Biotech (NCMB). NCMB
owns and operates a U.S. Patent for cannabis extraction
process. With the acquisition of NCMB, KALY is now primarily
in the business of developing biopharmaceutical formulations from
cannabis extractions for the treatment of various diseases.
KALY now has over four years of research and development behind
cannabis extract formulations targeting the treatment of
Chronic Obstructive Pulmonary Disease
(COPD), Cancer Pain Management, Type 2 Diabetes and
Epilepsy.
KALY has implemented a long-term
sustainable overall business strategy. KALY is not just
relying on its biopharmaceutical development strategy alone to
insure the company’s long-term success. KALY, through
partnership and independently, has also introduced to market a
number of CBD infused consumer food products and a new CBD
extraction service for hemp farming operations.
250% 2019 YTD Revenue
Growth
The revenue realized in the first six
months of 2019 comes primarily from KALY’s various CBD infusion
offerings. KALY realized $165,000 in revenue in the first six
months of 2019. The revenue results from the company’s
cannabis business shift in the fourth quarter of last year.
In the first six months of 2018, KALY reported only $46,000 in
sales. The introduction of KALY’s new cannabis business has
seen the company’s revenue grow over 250% in the first six months
of 2019 compared to the first six months of 2018. KALY also
realized $70,000 in operating net income in the first six months of
2019. KALY reported only nominal operating net income in the
first six months of 2018.
More Dramatic Revenue Growth
Anticipated 2nd Half Of 2019
Drawing on KALY’s patented cannabis
extraction expertise, the company has recently announced $15
million worth of extraction contracts with hemp farming operations.
KALY management anticipates even more
dramatic revenue growth in the second half of 2019 as hemp harvest
season approaches.
Updated KALY Analyst Report
Planned For Publication Next Week
In addition to the corporate financial
disclosures released yesterday, KALY’s alternative reporting site,
www.kaly-info.com, includes an analyst report on
KALY’s overall business operation in addition to other useful
information. In conjunction with the recent cannabis extract
biopharmaceutical business updates made this week, KALY anticipates
publishing an updated analyst report next week.
To learn more about the company visit
https://www.kali-extracts.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214) 210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Apr 2023 to Apr 2024